294. Congenital diaphragmatic hernia
[
7 clinical trials,
12 drugs（DrugBank:
4 drugs),
5 target genes / 14 target pathways ]
Searched query = "Congenital diaphragmatic hernia"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03526588 | August 1, 2018 | 29 April 2019 | Umbilical Cord Blood Mononuclear Cells for Hypoxic Neurologic Injury in Infants With Congenital Diaphragmatic Hernia (CDH) | Umbilical Cord Blood Mononuclear Cells for Hypoxic Neurologic Injury in Infants With Congenital Diaphragmatic Hernia (CDH) | Congenital Diaphragmatic Hernia | Biological: Autologous umbilical cord blood | The University of Texas Health Science Center, Houston | Texas Medical Center Regenerative Medicine Consortium | Recruiting | N/A | 7 Days | All | 20 | Phase 1 | United States |
| 2 | EUCTR2017-000421-13-AT | 13/07/2018 | 23 July 2018 | Treatment of high blood pressure in the lungs in newborns with a defect in the diaphragm; inhaled Nitric Oxide compared to intravenous Sildenafil. | Newborns with Congenital Diaphragmatic hernia: inhaled Nitric Oxide versus intravenous Sildenafil: an international randomized controlled trial - CoDiNOS trial | Congenital diaphragmatic hernia with pulmonary hypertension;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: revatio 0.8mg/ml solution for injection Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: Sildenafil CAS Number: 171599-83-0 Concentration unit: mg/kg milligram(s)/kilogram Concentration type: equal Concentration number: 0.4- Trade Name: INOmax 800ppm mol/mol inhalatiegas Pharmaceutical Form: Medicinal gas, compressed INN or Proposed INN: NITRIC OXIDE CAS Number: 10102-43-9 Concentration unit: PPM part per million Concentration type: equal Concentration number: 20- | Erasmus MC | Authorised | Female: yes Male: yes | 330 | Phase 4 | Austria;Netherlands | |||
| 3 | NCT03787160 | March 22, 2018 | 26 August 2019 | Microbiome and Volatile Organic Compounds in Patients With CDH | Determining the Effect of Probiotics on Microbiome and Volatile Organic Compounds in Patients After Surgical Repair of Congenital Diaphragmatic Hernia | Congenital Diaphragmatic Hernia | Diagnostic Test: initial VOC;Diagnostic Test: initial fecal microbiome;Diagnostic Test: initial pulmonary microbiome;Diagnostic Test: Maximum oxygen uptake;Diagnostic Test: Functional residual capacity;Dietary Supplement: Probiotic treatment;Diagnostic Test: VOC probiotic;Diagnostic Test: Fecal microbiome probiotic;Diagnostic Test: Pulmonary microbiome probiotic | Medical University of Graz | University of Rostock | Not recruiting | 6 Years | 16 Years | All | 20 | N/A | Austria |
| 4 | NCT02951130 | August 22, 2017 | 25 March 2019 | Milrinone in Congenital Diaphragmatic Hernia | Milrinone in Congenital Diaphragmatic Hernia | Congenital Diaphragmatic Hernia;Persistent Pulmonary Hypertension of the Newborn;Hypoxemic Respiratory Failure;Pulmonary Hypoplasia | Drug: Milrinone;Drug: Placebo (5% Dextrose) | NICHD Neonatal Research Network | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Recruiting | N/A | 168 Hours | All | 66 | Phase 2 | United States |
| 5 | EUCTR2017-000421-13-NL | 27/07/2017 | 21 August 2017 | Treatment of high blood pressure in the lungs in newborns with a defect in the diaphragm; inhaled Nitric Oxide compared to intravenous Sildenafil. | Newborns with Congenital Diaphragmatic hernia: inhaled Nitric Oxide versus intravenous Sildenafil: an international randomized controlled trial - CoDiNOS trial | Congenital diaphragmatic hernia with pulmonary hypertension;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: revatio 0.8mg/ml solution for injection Pharmaceutical Form: Solution for injection/infusion Trade Name: INOmax 800ppm mol/mol inhalatiegas Pharmaceutical Form: Medicinal gas, compressed INN or Proposed INN: NITRIC OXIDE CAS Number: 10102-43-9 Trade Name: Neophyr 1000ppm mol/mol Pharmaceutical Form: Medicinal gas, compressed | Erasmus MC | Authorised | Female: yes Male: yes | 330 | Phase 3 | Netherlands | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT02453750 | February 2012 | 1 June 2015 | Airway Inflammation in Congenital Diaphragmatic Hernia Patients | Investigation of Airway Inflammation in Congenital Diaphragmatic Hernia Patients | Congenital Diaphragmatic Hernia | Drug: Hypersaline;Drug: Bronchodilator Response | The Hospital for Sick Children | Not recruiting | 6 Years | 18 Years | Both | 21 | N/A | Canada | |
| 7 | NCT00226044 | September 2005 | 22 October 2019 | Rectal and Oral Omeprazole Treatment of Reflux Disease in Infants. | Rectal and Oral Omeprazole Treatment of Gastroesophageal Reflux in Infants With Esophageal Atresia or Congenital Diaphragmatic Hernia; A Pharmacodynamic and Pharmacokinetic Study. | Gastroesophageal Reflux;Esophageal Atresia;Hernia, Diaphragmatic | Drug: Omeprazole rectally 1mg/kg | Rijnstate Hospital | Erasmus Medical Center | Not recruiting | 6 Weeks | 3 Months | All | 17 | Phase 3 | Netherlands |